alexa New Insights into Diagnosis of Monoclonal Gammopathy of Undetermined Significance:Emerging Role of Micro RNAs | Open Access Journals
ISSN: 2329-8790
Journal of Hematology & Thromboembolic Diseases
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

New Insights into Diagnosis of Monoclonal Gammopathy of Undetermined Significance:Emerging Role of Micro RNAs

Adel Gouri1*Aoulia Dekaken2Ahmed Aimen Bentorki1Amina Yakhlef3Mehdi Beleilli4Faiza Mehiddine5Nabil Mohie Abdelhamid6
1Laboratory of Medical Biochemistry, IBN ZOHR Public Hospital, Guelma 24000, Algeria
2Department of Internal Medicine; Pr EL OKBI Public Hospital, Guelma 24000, Algeria
3Department of Hematology, IBN ZOHR Public Hospital, Guelma 24000, Algeria
4Laboratory of Pharmaceutical Chemistry, College of Medicine, Annaba 2300, Algeria
5Department of Pneumology, IBN ZOHR Public Hospital, Guelma 24000, Algeria
6Department of Biochemistry, College of Pharmacy, Kafrelsheikh University, Egypt
Corresponding Author : Adel Gouri
Head of Laboratory of Medical Biochemistry
IBN ZOHR Public Hospital, Guelma, Algeria
Tel: 00213666088226
E-mail: [email protected]
Received December 18, 2013; Accepted January 06, 2014; Published January 06, 2014
Citation: Gouri A, Dekaken A, Bentorki AA, Yakhlef A, Beleilli M, et al. (2014) New Insights into Diagnosis of Monoclonal Gammopathy of Undetermined Significance: Emerging Role of Micro RNAs. J Hematol Thromb Dis 2:126. doi:10.4172/2329-8790.1000126
Copyright: © 2014 Gouri A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Hematology & Thromboembolic Diseases

Dear editor,
Despite the recent advances in the understanding of pathogenic mechanisms and the introduction of new therapeutic regimens, Monoclonal Gammopathy of Undetermined Significance (MGUS) continues to be a diagnostic and therapeutic challenge for both clinicians and laboratory practitioners.
Recent studies have shown that (MGUS) is a premalignant stage, which can progress to Multiple Myeloma (MM) or related plasma cell disorders. MGUS is present in over 3% of the population above the age of 50, and progresses to myeloma or related malignancy a rate of 1% per year [1].
MicroRNAs (miRs) are short sequences (22-25 nucleotides) of noncoding RNA molecules that regulate a range of biological processes by inducing RNA degradation and/or translation inhibition of targeted mRNAs [2]. miR alterations have been observed in various types of hematological malignancies, including MGUS and MM.
As posttranscriptional regulators of gene expression, miRNAs can act both as oncogenes and tumor suppressor genes demonstrating an important role in the pathogenesis and prognosis of hematological malignancies. The importance of miRNA dysregulation in the pathogenesis of MGUS is implied by the fact that miRNAs play pivotal roles in lineage differentiation and hematopoiesis regulation [3].
Recently, several studies have investigated the efficacy of miRs as diagnostic or prognostic biomarkers in MGUS and MM malignancies, found several deregulated miRNAs (i.e., miR-21, miR-744, let-7e, miR-130a and miR-34a) compared to healthy donors and implicated miRNAs in signaling pathways deregulated in MGUS pathogenesis [4,5].
More recently, Kubiczkova et al. have found that association of miR-34a and let-7e can distinguish MGUS patients from healthy donors with sensitivity of 91.1% and specificity of 96.7% [6].
The use of miRNAs as biomarkers has greatly increased as a result of the discovery that they are present in the circulating blood. A number of groups have shown that miRNAs can be detected in human serum or plasma, where they are thought to be protected from degradation by being encapsulated in microvesicles or exosomes and/or are bound by RNA-binding proteins such as Ago2 and nucleophosmin [7].
In addition to their potential use as diagnosis biomarker, miRs may represent a useful tool in predicting the clinical outcome of a disease or even identifying subgroups of patients at high risk, to develop early intervention strategies [8].
The miRNA field continues to grow at a phenomenal rate and new roles for miRNAs in biological and disease processes are constantly being discovered. However, more studies are needed to reveal the full potential of these small molecules.
References








Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11626
  • [From(publication date):
    January-2014 - Aug 20, 2017]
  • Breakdown by view type
  • HTML page views : 7837
  • PDF downloads :3789
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords